O uso da dexmedetomidina ou xilazina associados ao butorfanol na sedação de gatos pediátricos: estudo dos parâmetros clínicos e ecocardiográficos

Abstract

The use of the 2 adrenergic agonists has benefits in clinical anesthesiology, especially dexmedetomidine, because of its pharmacological aspect and high specificity. However, its advantages and disadvantages should be better elucidated through clinical studies in both Human and Veterinary Medicine. It is also of the group of 2 adrenergic agonists drugs such as xylazine, detomidine, medetomidine, clonidine and romifidine, the first two being the most used in veterinary medicine routine in Brazil. The aim of the present study was to evaluate the cat's heart rate, respiratory rate, systolic blood pressure, SpO2, ETCO2, rectal temperature, glycemia, sedation quality by means of simple descriptive scales of sedation scores, relaxation muscle and posture and to evaluate by echocardiogram the cardiovascular effects of 2 agents associated with butorphanol. Eighteen cats were selected, with weights around 1.5 +/- 0.14 kg, without distinction of brand and sex, and approximately 4 weeks to 6 months of age. The parameters were evaluated by thoracic auscultation; capnography; pulse oximeter; vascular Doppler; thermometer; frozen serum and echocardiogram. In the present study, 2 agonist drugs in neonatal cats did not affect the clinical parameters evaluated, except for glycemia, which increased up to 60 minutes after intramuscular administration. Echocardiography showed that xylazine was more deleterious to dexmedetomidine in most of the parameters evaluated, leading to a significant reduction in cardiac output.